EASL Journal Club
Now on demand!
Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab
EASL Quiz
Time for the new EASL Quiz
Test your Guidelines Knowledge!
EASL Studio
Wednesday 1 May, 18:00 CET
Assessment of clinically significant portal hypertension in 2024 – Is it time to say goodbye to invasive measurements?
EASL Molecular Tumour Board
On demand!
Catch up with the presentation and discussion of this clinical case of cholangiocarcinoma.
Steatotic liver disease – the missing piece in the NCD puzzle
Now on-demand!
Discover the priorities and recommendations for the upcoming WHA77 agenda established by EASL, representatives from the WHO, patient advocate, NCD Alliance, and more !
You may also be interested in
Our Sponsors